COLLABORATION WILL FOCUS ON COLLECTION, PROCESSING AND STORAGE OF EQUINE
CORD BLOOD, BONE MARROW AND PLACENTAL TISSUE STEM CELLS
RANCHO CORDOVA, Calif., Feb. 27 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, announced today that its wholly-owned subsidiary, Vantus, Inc., has signed a formal agreement with the UC Davis School of Veterinary Medicine's Center for Equine Health and its Stem Cell Regenerative Medicine Group. Under the agreement, the two organizations will conduct joint research and development of methods to enhance the collecting, processing and storing of stem cells from equine cord blood, bone marrow and placental tissue. These cells will be used in the development of therapeutics for the prevention and treatment of orthopedic injuries, such as tendon and ligament injuries, in performance horses.
Earlier this month, ThermoGenesis announced the creation of Vantus, a laboratory service company focused on the performance equine market, including Thoroughbreds, American Quarter Horses, Arabians and Warm Bloods. Under this collaboration, the ThermoGenesis MarrowXpress(TM) System and BioArchive(R) System will be used for processing and storage of the stem cells. The Company is currently refining collection methodologies at breeder farms in California and processing methods at UC Davis. Vantus expects to be in operation at the beginning of the foaling season in January of next year.
"As we have indicated, launching Vantus represents a major milestone in our regenerative medicine diversification strategy. By partnering with UC Davis, we are joining forces with a recognized world leader in veterinary medicine for the development of innovative therapies for treatment of injuries and disease in animals," noted Dr. William Osgood, Chief Executive Officer of ThermoGenesis.
"The risk of orthopedic injury to these high-value horses and their racing careers is well known. The potential for the use of stem cells to treat these debilitating, and often life-threatening, injuries is significant and we look forward to working with UC Davis on creating new forms of therapy for these horses," he added.
"The opportunities for stem-cell based therapies are significant and being proven every day. Leading veterinarians are now using stem cells in a variety of clinical conditions and the outcomes are very encouraging. We look forward to partnering with Vantus on the advancement of scientific discoveries and breakthroughs in this area," said Dr. Gregory Ferraro of the UC Davis Center for Equine Health.
"This is a market opportunity with great potential and we believe our clinically proven stem cell processing and cryopreservation technologies coupled with the research we are funding at the UC Davis Center for Equine Health can provide us important competitive advantages. Stem cell therapies are working and the regulatory hurdles in the veterinary medicine are relatively low. As a result, we are well-positioned to realize rapid growth in this business and make it an important contributor to shareholder value. In addition, we look forward to translating the lessons learned in the equine market to stem cell-based therapies for orthopedic injuries in humans so as to expand our presence in that market as well," Osgood noted.
Four leading clinicians from UC Davis will direct the collaboration
with Vantus. They include:
-- Gregory L. Ferraro, DVM has been the Director of the Center for Equine
Health, at the UC Davis, School of Veterinary Medicine since 1998.
Prior to his full time university appointment he was engaged in private
practice, specializing in racing thoroughbred medicine and surgery. Dr.
Ferraro is internationally recognized for his knowledge and expertise
in equine athletic injuries and has over 35 years of experience in that
field. He also served as Clinical Professor of Surgery at UC Davis for
many years during and after his private practice career. His interest
in advanced therapies for equine injuries stems from years of practical
clinical challenges and the scientific research for more effective and
timely therapeutic interventions.
-- Dori L. Borjesson, DVM, MPVM, PhD, DACVP, is Associate Professor of
veterinary clinical pathology with the Department of Pathology,
Microbiology and Immunology, at the UC Davis School of Veterinary
Medicine. She is a diplomat of the American College of Veterinary
Pathology with specialty boards in clinical pathology. Dr. Borjesson's
research has focused on bacterial interactions with hematopoietic
progenitor cells and mechanisms of bacterial-induced alterations in
bone marrow proliferation and differentiation. She has extensive in
vivo and in vitro experience with murine and human cells including
cord-blood derived stem cells.
-- Larry Galuppo DVM, Dipl. ACVS, Associate Professor and Chief, Equine
Surgery, Department of Surgical & Radiological Sciences, UC Davis
School of Veterinary Medicine. Clinical expertise in equine orthopedic
surgery including tendon and ligament injuries, joint disease, with
special interest in traumatology and fracture repair. Research emphasis
on biomechanics of fracture generation, implant design and fracture
repair, with focus in novel healing methods for musculoskeletal
injuries utilizing regenerative medicine technology.
-- Sean D. Owens, DVM, MRCVS, DACVP, is Assistant Professor of Clinical
Diagnostic/Clinical Pathology at the UC Davis School of Veterinary
Medicine, Medical Director of the UC Davis Animal Blood Bank and head
of the Transfusion Medicine Service at the UC Davis Veterinary Medical
Teaching Hospital. Dr. Owens' expertise is in cord blood collection,
cord blood processing and cryopreservation of cord blood-derived stem
cells. His current research efforts focus on transfusion-related
compatibility issues in horses, focusing on stem cell transplants and
To learn more about Vantus please log onto http://www.vantuslabs.com.
About ThermoGenesis Corp.
ThermoGenesis Corp. (http://www.thermogenesis.com) is a leading
supplier of innovative products and services that process and store adult
stem cells for treatment of disease and injury. These products include:
-- The BioArchive(R) System, an automated cryogenic device, is used by
cord blood stem cell banks in more than 25 countries for
cryopreserving and archiving cord blood stem cell units for transplant.
-- AXP(TM) AutoXpress(TM) System is used for the processing of cord blood
including sterile blood processing disposable for harvesting stem
cells in a closed system.
-- AXP(TM) MarrowXpress(TM) is used for isolating stem cells from bone
marrow in a closed system.
-- The CryoSeal(R) FS System, an automated device and companion sterile
blood processing disposable, is used to prepare fibrin sealants from
plasma in about an hour.
-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood
processing disposable that prepares activated thrombin from a small
aliquot of plasma in less than 30 minutes.
This press release, including statements regarding financial
information for future periods, contain forward-looking statements, and
such statements are made pursuant to the safe harbour provisions of the
Private Securities Litigation Reform Act of 1995. These statements involve
risks and uncertainties that could cause actual outcomes to differ
materially from those contemplated by the forward-looking statements.
Several factors, including timing of FDA approvals, changes in customer
forecasts, our failure to meet customers' purchase order and quality
requirements, supply shortages, production delays, changes in the markets
for customers' products, introduction timing and acceptance of our new
products scheduled for fiscal year 2008, and introduction of competitive
products and other factors beyond our control, could result in a materially
different revenue outcome and/or in our failure to achieve the revenue
levels we expect for fiscal 2008. A more complete description of these and
other risks that could cause actual events to differ from the outcomes
predicted by our forward looking statements is set forth under the caption
"Risk Factors" in our annual report on Form 10-K and other reports we file
with the Securities and Exchange Commission from time to time, and you
should consider each of those factors when evaluating the forward looking
Web site: http://www.thermogenesis.com
Web site: http://www.vantuslabs.com
Contact: Investor Relations
|SOURCE ThermoGenesis Corp.|
Copyright©2008 PR Newswire.
All rights reserved